Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.68 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.57 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18798890 | 0.91 | FFAR1 (0.60) | FFAR1S1PR1S1PR3 | |
| SCHEMBL5020719 | 0.87 | MAOB (0.55) | — | |
| SCHEMBL4657988 | 0.87 | FFAR1 (0.76) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL18798799 | 0.85 | PARP10 (0.64) | FFAR1 | |
| SCHEMBL18798798 | 0.85 | MAPT (0.58) | — | |
| SCHEMBL5020711 | 0.84 | CA2 (0.55) | — | |
| SCHEMBL6060917 | 0.83 | PARP10 (0.71) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL9136277 | 0.83 | TAAR1 (0.66) | S1PR1S1PR3S1PR5 | |
| SCHEMBL12688084 | 0.82 | FFAR1 (0.65) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL12688087 | 0.82 | HDAC6 (0.67) | FFAR1S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| EP-2813227-A1 | Compositions for treatment of cystic fibrosis and other chronic diseases | Vertex Pharmaceuticals Incorporated (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| US-8697687-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130012500-A1 | ORGANIC COMPOUNDS | BHALAY GURDIP (GB) | 2013-01-10 | — | — | US | disclosed |
| EP-2231280-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
| WO-2009074575-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012500-A1 | ORGANIC COMPOUNDS | OR10J3, REN, CACNA1E | FFAR1 179/4885S1PR1 287/4885S1PR3 303/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | FFAR1 1054/4885S1PR1 1005/4885S1PR3 1001/4885 |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | FFAR1 302/4885S1PR1 330/4885S1PR3 283/4885 |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | FFAR1 1054/4885S1PR1 1005/4885S1PR3 1001/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | FFAR1 1054/4885S1PR1 1005/4885S1PR3 1001/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | FFAR1 179/4885S1PR1 287/4885S1PR3 303/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | FFAR1 1054/4885S1PR1 1005/4885S1PR3 1001/4885 |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | FFAR1 302/4885S1PR1 330/4885S1PR3 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.